Copyright Reports & Markets. All rights reserved.

Global Obesity Hypoventilation Syndrome Treatment Market Growth (Status and Outlook) 2022-2028

Request for Sample of this report
Buy now

1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global Obesity Hypoventilation Syndrome Treatment Market Size 2017-2028
    • 2.1.2 Obesity Hypoventilation Syndrome Treatment Market Size CAGR by Region 2017 VS 2022 VS 2028
  • 2.2 Obesity Hypoventilation Syndrome Treatment Segment by Type
    • 2.2.1 Oxygen Therapy
    • 2.2.2 Non-invasive Mechanical Ventilation
    • 2.2.3 Drug Therapy
    • 2.2.4 Other
  • 2.3 Obesity Hypoventilation Syndrome Treatment Market Size by Type
    • 2.3.1 Obesity Hypoventilation Syndrome Treatment Market Size CAGR by Type (2017 VS 2022 VS 2028)
    • 2.3.2 Global Obesity Hypoventilation Syndrome Treatment Market Size Market Share by Type (2017-2022)
  • 2.4 Obesity Hypoventilation Syndrome Treatment Segment by Application
    • 2.4.1 Hospital
    • 2.4.2 Clinics
    • 2.4.3 Others
  • 2.5 Obesity Hypoventilation Syndrome Treatment Market Size by Application
    • 2.5.1 Obesity Hypoventilation Syndrome Treatment Market Size CAGR by Application (2017 VS 2022 VS 2028)
    • 2.5.2 Global Obesity Hypoventilation Syndrome Treatment Market Size Market Share by Application (2017-2022)

3 Obesity Hypoventilation Syndrome Treatment Market Size by Player

  • 3.1 Obesity Hypoventilation Syndrome Treatment Market Size Market Share by Players
    • 3.1.1 Global Obesity Hypoventilation Syndrome Treatment Revenue by Players (2020-2022)
    • 3.1.2 Global Obesity Hypoventilation Syndrome Treatment Revenue Market Share by Players (2020-2022)
  • 3.2 Global Obesity Hypoventilation Syndrome Treatment Key Players Head office and Products Offered
  • 3.3 Market Concentration Rate Analysis
    • 3.3.1 Competition Landscape Analysis
    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
  • 3.4 New Products and Potential Entrants
  • 3.5 Mergers & Acquisitions, Expansion

4 Obesity Hypoventilation Syndrome Treatment by Regions

  • 4.1 Obesity Hypoventilation Syndrome Treatment Market Size by Regions (2017-2022)
  • 4.2 Americas Obesity Hypoventilation Syndrome Treatment Market Size Growth (2017-2022)
  • 4.3 APAC Obesity Hypoventilation Syndrome Treatment Market Size Growth (2017-2022)
  • 4.4 Europe Obesity Hypoventilation Syndrome Treatment Market Size Growth (2017-2022)
  • 4.5 Middle East & Africa Obesity Hypoventilation Syndrome Treatment Market Size Growth (2017-2022)

5 Americas

  • 5.1 Americas Obesity Hypoventilation Syndrome Treatment Market Size by Country (2017-2022)
  • 5.2 Americas Obesity Hypoventilation Syndrome Treatment Market Size by Type (2017-2022)
  • 5.3 Americas Obesity Hypoventilation Syndrome Treatment Market Size by Application (2017-2022)
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC Obesity Hypoventilation Syndrome Treatment Market Size by Region (2017-2022)
  • 6.2 APAC Obesity Hypoventilation Syndrome Treatment Market Size by Type (2017-2022)
  • 6.3 APAC Obesity Hypoventilation Syndrome Treatment Market Size by Application (2017-2022)
  • 6.4 China
  • 6.5 Japan
  • 6.6 Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia

7 Europe

  • 7.1 Europe Obesity Hypoventilation Syndrome Treatment by Country (2017-2022)
  • 7.2 Europe Obesity Hypoventilation Syndrome Treatment Market Size by Type (2017-2022)
  • 7.3 Europe Obesity Hypoventilation Syndrome Treatment Market Size by Application (2017-2022)
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa Obesity Hypoventilation Syndrome Treatment by Region (2017-2022)
  • 8.2 Middle East & Africa Obesity Hypoventilation Syndrome Treatment Market Size by Type (2017-2022)
  • 8.3 Middle East & Africa Obesity Hypoventilation Syndrome Treatment Market Size by Application (2017-2022)
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends

10 Global Obesity Hypoventilation Syndrome Treatment Market Forecast

  • 10.1 Global Obesity Hypoventilation Syndrome Treatment Forecast by Regions (2023-2028)
    • 10.1.1 Global Obesity Hypoventilation Syndrome Treatment Forecast by Regions (2023-2028)
    • 10.1.2 Americas Obesity Hypoventilation Syndrome Treatment Forecast
    • 10.1.3 APAC Obesity Hypoventilation Syndrome Treatment Forecast
    • 10.1.4 Europe Obesity Hypoventilation Syndrome Treatment Forecast
    • 10.1.5 Middle East & Africa Obesity Hypoventilation Syndrome Treatment Forecast
  • 10.2 Americas Obesity Hypoventilation Syndrome Treatment Forecast by Country (2023-2028)
    • 10.2.1 United States Obesity Hypoventilation Syndrome Treatment Market Forecast
    • 10.2.2 Canada Obesity Hypoventilation Syndrome Treatment Market Forecast
    • 10.2.3 Mexico Obesity Hypoventilation Syndrome Treatment Market Forecast
    • 10.2.4 Brazil Obesity Hypoventilation Syndrome Treatment Market Forecast
  • 10.3 APAC Obesity Hypoventilation Syndrome Treatment Forecast by Region (2023-2028)
    • 10.3.1 China Obesity Hypoventilation Syndrome Treatment Market Forecast
    • 10.3.2 Japan Obesity Hypoventilation Syndrome Treatment Market Forecast
    • 10.3.3 Korea Obesity Hypoventilation Syndrome Treatment Market Forecast
    • 10.3.4 Southeast Asia Obesity Hypoventilation Syndrome Treatment Market Forecast
    • 10.3.5 India Obesity Hypoventilation Syndrome Treatment Market Forecast
    • 10.3.6 Australia Obesity Hypoventilation Syndrome Treatment Market Forecast
  • 10.4 Europe Obesity Hypoventilation Syndrome Treatment Forecast by Country (2023-2028)
    • 10.4.1 Germany Obesity Hypoventilation Syndrome Treatment Market Forecast
    • 10.4.2 France Obesity Hypoventilation Syndrome Treatment Market Forecast
    • 10.4.3 UK Obesity Hypoventilation Syndrome Treatment Market Forecast
    • 10.4.4 Italy Obesity Hypoventilation Syndrome Treatment Market Forecast
    • 10.4.5 Russia Obesity Hypoventilation Syndrome Treatment Market Forecast
  • 10.5 Middle East & Africa Obesity Hypoventilation Syndrome Treatment Forecast by Region (2023-2028)
    • 10.5.1 Egypt Obesity Hypoventilation Syndrome Treatment Market Forecast
    • 10.5.2 South Africa Obesity Hypoventilation Syndrome Treatment Market Forecast
    • 10.5.3 Israel Obesity Hypoventilation Syndrome Treatment Market Forecast
    • 10.5.4 Turkey Obesity Hypoventilation Syndrome Treatment Market Forecast
    • 10.5.5 GCC Countries Obesity Hypoventilation Syndrome Treatment Market Forecast
  • 10.6 Global Obesity Hypoventilation Syndrome Treatment Forecast by Type (2023-2028)
  • 10.7 Global Obesity Hypoventilation Syndrome Treatment Forecast by Application (2023-2028)

11 Key Players Analysis

  • 11.1 Accord Healthcare Limited
    • 11.1.1 Accord Healthcare Limited Company Information
    • 11.1.2 Accord Healthcare Limited Obesity Hypoventilation Syndrome Treatment Product Offered
    • 11.1.3 Accord Healthcare Limited Obesity Hypoventilation Syndrome Treatment Revenue, Gross Margin and Market Share (2020-2022)
    • 11.1.4 Accord Healthcare Limited Main Business Overview
    • 11.1.5 Accord Healthcare Limited Latest Developments
  • 11.2 Avet Pharmaceuticals Inc
    • 11.2.1 Avet Pharmaceuticals Inc Company Information
    • 11.2.2 Avet Pharmaceuticals Inc Obesity Hypoventilation Syndrome Treatment Product Offered
    • 11.2.3 Avet Pharmaceuticals Inc Obesity Hypoventilation Syndrome Treatment Revenue, Gross Margin and Market Share (2020-2022)
    • 11.2.4 Avet Pharmaceuticals Inc Main Business Overview
    • 11.2.5 Avet Pharmaceuticals Inc Latest Developments
  • 11.3 Nostrum Laboratories Inc
    • 11.3.1 Nostrum Laboratories Inc Company Information
    • 11.3.2 Nostrum Laboratories Inc Obesity Hypoventilation Syndrome Treatment Product Offered
    • 11.3.3 Nostrum Laboratories Inc Obesity Hypoventilation Syndrome Treatment Revenue, Gross Margin and Market Share (2020-2022)
    • 11.3.4 Nostrum Laboratories Inc Main Business Overview
    • 11.3.5 Nostrum Laboratories Inc Latest Developments
  • 11.4 Lannett Co Inc
    • 11.4.1 Lannett Co Inc Company Information
    • 11.4.2 Lannett Co Inc Obesity Hypoventilation Syndrome Treatment Product Offered
    • 11.4.3 Lannett Co Inc Obesity Hypoventilation Syndrome Treatment Revenue, Gross Margin and Market Share (2020-2022)
    • 11.4.4 Lannett Co Inc Main Business Overview
    • 11.4.5 Lannett Co Inc Latest Developments
  • 11.5 Strides Pharma Science Limited
    • 11.5.1 Strides Pharma Science Limited Company Information
    • 11.5.2 Strides Pharma Science Limited Obesity Hypoventilation Syndrome Treatment Product Offered
    • 11.5.3 Strides Pharma Science Limited Obesity Hypoventilation Syndrome Treatment Revenue, Gross Margin and Market Share (2020-2022)
    • 11.5.4 Strides Pharma Science Limited Main Business Overview
    • 11.5.5 Strides Pharma Science Limited Latest Developments
  • 11.6 X Gen Pharmaceuticals Inc
    • 11.6.1 X Gen Pharmaceuticals Inc Company Information
    • 11.6.2 X Gen Pharmaceuticals Inc Obesity Hypoventilation Syndrome Treatment Product Offered
    • 11.6.3 X Gen Pharmaceuticals Inc Obesity Hypoventilation Syndrome Treatment Revenue, Gross Margin and Market Share (2020-2022)
    • 11.6.4 X Gen Pharmaceuticals Inc Main Business Overview
    • 11.6.5 X Gen Pharmaceuticals Inc Latest Developments
  • 11.7 ResMed
    • 11.7.1 ResMed Company Information
    • 11.7.2 ResMed Obesity Hypoventilation Syndrome Treatment Product Offered
    • 11.7.3 ResMed Obesity Hypoventilation Syndrome Treatment Revenue, Gross Margin and Market Share (2020-2022)
    • 11.7.4 ResMed Main Business Overview
    • 11.7.5 ResMed Latest Developments
  • 11.8 Koninklijke Philips NV
    • 11.8.1 Koninklijke Philips NV Company Information
    • 11.8.2 Koninklijke Philips NV Obesity Hypoventilation Syndrome Treatment Product Offered
    • 11.8.3 Koninklijke Philips NV Obesity Hypoventilation Syndrome Treatment Revenue, Gross Margin and Market Share (2020-2022)
    • 11.8.4 Koninklijke Philips NV Main Business Overview
    • 11.8.5 Koninklijke Philips NV Latest Developments
  • 11.9 Hikma Pharmaceuticals
    • 11.9.1 Hikma Pharmaceuticals Company Information
    • 11.9.2 Hikma Pharmaceuticals Obesity Hypoventilation Syndrome Treatment Product Offered
    • 11.9.3 Hikma Pharmaceuticals Obesity Hypoventilation Syndrome Treatment Revenue, Gross Margin and Market Share (2020-2022)
    • 11.9.4 Hikma Pharmaceuticals Main Business Overview
    • 11.9.5 Hikma Pharmaceuticals Latest Developments
  • 11.10 Lincare Holdings
    • 11.10.1 Lincare Holdings Company Information
    • 11.10.2 Lincare Holdings Obesity Hypoventilation Syndrome Treatment Product Offered
    • 11.10.3 Lincare Holdings Obesity Hypoventilation Syndrome Treatment Revenue, Gross Margin and Market Share (2020-2022)
    • 11.10.4 Lincare Holdings Main Business Overview
    • 11.10.5 Lincare Holdings Latest Developments

12 Research Findings and Conclusion

Obesity hypoventilation syndrome is defined as alveolar hypoventilation while awake in an obese individual where there is no other cause of the hypoventilation (such as a sedating drug). Ninety percent of people with obesity hypoventilation syndrome (OHS) also have an associated obstructive sleep apnea.The mainstay of treatment in OHS is to provide breathing support, often through the use of continuous positive airway pressure (CPAP) or bilevel.

The global market for Obesity Hypoventilation Syndrome Treatment is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC Obesity Hypoventilation Syndrome Treatment market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States Obesity Hypoventilation Syndrome Treatment market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe Obesity Hypoventilation Syndrome Treatment market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China Obesity Hypoventilation Syndrome Treatment market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key Obesity Hypoventilation Syndrome Treatment players cover Accord Healthcare Limited, Avet Pharmaceuticals Inc, Nostrum Laboratories Inc, Lannett Co Inc and Strides Pharma Science Limited, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

Report Coverage
This latest report provides a deep insight into the global Obesity Hypoventilation Syndrome Treatment market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global Obesity Hypoventilation Syndrome Treatment market, with both quantitative and qualitative data, to help readers understand how the Obesity Hypoventilation Syndrome Treatment market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.

Market Segmentation:
The study segments the Obesity Hypoventilation Syndrome Treatment market and forecasts the market size by Type (Oxygen Therapy, Non-invasive Mechanical Ventilation and Drug Therapy), by Application (Hospital, Clinics and Others,), and region (APAC, Americas, Europe, and Middle East & Africa).

Segmentation by type
Oxygen Therapy
Non-invasive Mechanical Ventilation
Drug Therapy
Other

Segmentation by application
Hospital
Clinics
Others

Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Major companies covered
Accord Healthcare Limited
Avet Pharmaceuticals Inc
Nostrum Laboratories Inc
Lannett Co Inc
Strides Pharma Science Limited
X Gen Pharmaceuticals Inc
ResMed
Koninklijke Philips NV
Hikma Pharmaceuticals
Lincare Holdings

Chapter Introduction
Chapter 1: Scope of Obesity Hypoventilation Syndrome Treatment, Research Methodology, etc.
Chapter 2: Executive Summary, global Obesity Hypoventilation Syndrome Treatment market size and CAGR, Obesity Hypoventilation Syndrome Treatment market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Obesity Hypoventilation Syndrome Treatment revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Obesity Hypoventilation Syndrome Treatment revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Obesity Hypoventilation Syndrome Treatment market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Accord Healthcare Limited, Avet Pharmaceuticals Inc, Nostrum Laboratories Inc, Lannett Co Inc, Strides Pharma Science Limited, X Gen Pharmaceuticals Inc, ResMed, Koninklijke Philips NV and Hikma Pharmaceuticals, etc.
Chapter 14: Research Findings and Conclusion
Buy now